Sex hormone-binding globulin and thrombin generation in women using hormonal contraception

References

• Anžej Doma S, Vučnik M, Božič Mijovski M, et al. (2013). Enhanced thrombin generation in women with a history of oral contraception-related venous thrombosis. Thromb Res 132:621–6.
   PubMed Web of Science ®Google Scholar
• Barkfeldt J, Virkkunen A, Dieben T. (2001). The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 64:295–9.
   PubMed Web of Science ®Google Scholar
• Blanco-Molina MA, Lozano M, Cano A, et al. (2012). Progestin-only contraception and venous thromboembolism. Thromb Res 129:e257–62.
   PubMed Web of Science ®Google Scholar
• Carcaillon L, Alhenc-Gelas M, Bejot Y, et al. (2011). Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol 31:1445–51.
   PubMed Web of Science ®Google Scholar
• Dielis AWJH, Castoldi E, Spronk HMH, et al. (2008). Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 6:125–31.
   PubMed Web of Science ®Google Scholar
• Fleischer K, van Vliet HA, Rosendaal FR, et al. (2009). Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res 123:429–35.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Sidelmann JJ, Altinok ML, et al. (2015). Increased thrombin generation in women with polycystic ovary syndrome: a pilot study on the effect of metformin and oral contraceptives. Metabolism 64:1272–8.
   PubMed Web of Science ®Google Scholar
• Hapgood JP, Africander D, Louw R, et al. (2014). Potency of progestogens used in hormonal therapy: toward understanding differential actions. J Steroid Biochem Mol Biol 142:39–47.
   PubMed Web of Science ®Google Scholar
• Hemker HC, Giesen P, Al Dieri R, et al. (2003). Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33:4–15.
   PubMed Web of Science ®Google Scholar
• Hou H, Ge Z, Ying P, et al. (2012). Biomarkers of deep venous thrombosis. J Thromb Thrombolysis 34:335–46.
   PubMed Web of Science ®Google Scholar
• Hugon-Rodin J, Gompel A, Plu-Bureau G. (2014). Epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol Eur Fed Endocr Soc 171:R221–30.
   PubMed Web of Science ®Google Scholar
• Kluft C, Skouby SO, Jespersen J, Burggraaf J. (2013). Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal. J Thromb Haemost 11:394–5.
   PubMed Web of Science ®Google Scholar
• Kuhl H. (1996). Comparative pharmacology of newer progestogens. Drugs 51:188–215.
   PubMed Web of Science ®Google Scholar
• Lewis MR, Callas PW, Jenny NS, Tracy RP. (2001). Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 86:1495–500.
   PubMed Web of Science ®Google Scholar
• Mainwaring R, Hales HA, Stevenson K, et al. (1995). Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception 51:149–53.
   PubMed Web of Science ®Google Scholar
• Mantha S, Karp R, Raghavan V, et al. (2012). Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 345:e4944.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Imthurn B, Rosselli M, Spanaus K. (2011). Implanon use lowers plasma concentrations of high-molecular-weight adiponectin. Fertil Steril 95:23–7.
   PubMed Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, Victor A. (2002). Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 81:482–90.
   PubMed Web of Science ®Google Scholar
• Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. (2013). Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab 27:25–34.
   PubMed Web of Science ®Google Scholar
• Raps M, Helmerhorst F, Fleischer K, et al. (2012). Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost 10:992–7.
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Hemker HC, Clément C, et al. (2011). Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. Menopause N Y N 18:873–9.
   PubMed Web of Science ®Google Scholar
• Schindler AE. (2003). Differential effects of progestins on hemostasis. Maturitas 46:S31–7.
   PubMed Web of Science ®Google Scholar
• Sonnevi K, Tchaikovski SN, Holmström M, et al. (2013). Obesity and thrombin-generation profiles in women with venous thromboembolism. Blood Coagul Fibrinolysis Int J Haemost Thromb 24:547–53.
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Grimes DA. (2008). Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives. Contraception 78:201–3.
   PubMed Web of Science ®Google Scholar
• Stegeman BH, de Bastos M, Rosendaal FR, et al. (2013). Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 347:f5298.
   PubMed Web of Science ®Google Scholar
• Stegeman BH, Helmerhorst FM, Vos HL, et al. (2012). Sex hormone-binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives. J Thromb Haemost 10:2061–7.
   PubMed Web of Science ®Google Scholar
• Tans G, van Hylckama Vlieg A, Thomassen MCLGD, et al. (2003). Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 122:465–70.
   PubMed Web of Science ®Google Scholar
• Tchaikovski SN, Rosing J. (2010). Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 126:5–11.
   PubMed Web of Science ®Google Scholar
• Tchaikovski SN, Thomassen MCLGD, Costa SD, et al. (2014). Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives. Thromb Res 134:1032–7.
   PubMed Web of Science ®Google Scholar
• Tchaikovski SN, van Vliet HAAM, Thomassen MCLGD, et al. (2007). Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 98:1350–6.
   PubMed Web of Science ®Google Scholar
• Van Hylckama Vlieg A, Baglin CA, Luddington R, et al. (2015). The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study. J Thromb Haemost 13:1642–52.
   PubMed Web of Science ®Google Scholar
• Van Rooijen M, Silveira A, Hamsten A, Bremme K. (2004). Sex hormone-binding globulin – a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 190:332–7.
   PubMed Web of Science ®Google Scholar
• Van Vliet HAAM, Frolich M, Christella M, et al. (2005). Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod Oxf Engl 20:563–8.
   PubMed Web of Science ®Google Scholar
• Wodzicki AM, Coopland AT. (1972). Chlormadinone acetate and its effect on the hemostatic mechanism. Can Med Assoc J 107:38–41.
   PubMed Web of Science ®Google Scholar